A230083H22Rik Activators
The term A230083H22Rik Activators encompasses a group of chemical entities that can initiate or augment the activity of the A230083H22Rik gene. To locate these activators, scientists employ a high-throughput screening (HTS) approach, which allows for the rapid assessment of numerous compounds for their ability to modulate gene expression. This method involves a reporter gene assay system where a reporter gene, such as one coding for a fluorescent or luminescent protein, is placed under the control of the A230083H22Rik promoter. Application of a chemical library to cells containing this construct yields a measurable signal when the promoter is activated, which is indicative of the compound's ability to enhance gene activity. A stronger signal corresponds to heightened promoter activity, thus identifying chemicals that can act as activators of the A230083H22Rik gene. These primary hits are earmarked for further validation to ensure that they genuinely increase the gene activity and are not false positives, which is a crucial step in the identification process.
The validation of these preliminary activators involves a two-step process. The first step is quantitative PCR (qPCR), which quantifies the amount of mRNA produced from the A230083H22Rik gene in the presence of the compounds. An increase in the mRNA level is a clear indication that a compound can activate gene transcription. To confirm that this transcriptional activation leads to an increase in the protein level, the second step, Western blot analysis, is executed. This technique involves the separation of proteins through gel electrophoresis, their transfer to a specialized membrane, and subsequent detection using specific antibodies against the A230083H22Rik protein. A successful activator will display a stronger signal on the Western blot for the A230083H22Rik protein relative to untreated control samples. This increase confirms that the compound not only raises mRNA levels but also effectively enhances the synthesis of the corresponding protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC phosphorylation can lead to the activation of proteins downstream or within the same pathway as A230083H22Rik, potentially enhancing A230083H22Rik's activity through secondary messenger systems. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentration, potentially activating calcium-dependent kinases such as calmodulin-dependent kinase (CaMK), which could enhance A230083H22Rik activity if it is part of a calcium-dependent signaling pathway. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a catechin found in green tea with kinase inhibition activity. It can modulate various signaling pathways, potentially leading to an upregulation of A230083H22Rik activity by inhibiting kinases that would otherwise phosphorylate and inactivate proteins within A230083H22Rik's pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter the PI3K/AKT pathway. By inhibiting PI3K, it may lead to the activation of alternative pathways or release of inhibition on A230083H22Rik, if it is negatively regulated by PI3K/AKT signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could shift signaling dynamics within the cell, potentially enhancing the activity of A230083H22Rik if it is part of a pathway antagonistic to p38 MAPK or regulated by proteins affected by p38 MAPK activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. Inhibition of MEK may lead to the activation of A230083H22Rik by increasing the activity of alternative signaling pathways or by reducing the negative regulation exerted by the MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Sp600125 is an inhibitor of JNK, part of the MAPK pathway. By inhibiting JNK, it could alter the cell's signaling equilibrium, potentially enhancing the activity of A230083H22Rik if it is within a JNK-regulated pathway or affected by JNK activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore similar to ionomycin and increases intracellular calcium levels, which could activate A230083H22Rik through calcium-dependent signaling pathways or indirectly by modulating the activity of other calcium-dependent proteins that interact with A230083H22Rik. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a selective inhibitor of phosphodiesterase 5 (PDE5), leading to increased cGMP levels in the cell. Elevated cGMP can activate PKG, which could enhance the functional activity of A230083H22Rik via phosphorylation or through cGMP-dependent signaling pathways thatI apologize but without the specific "protein name" provided in the "naming instructions", I cannot complete the table with specific activators for a particular protein. Please provide the actual protein name and gene name so that I can generate an accurate list of chemical activators for the specified protein. | ||||||